Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Theodora Anagnostou, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Shahrzad Jalali, PhD, Jose C Villasboas, Hongyan Wu, PhD, Tammy Price-Troska, BS, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2790.

https://doi.org/10.1182/blood-2019-127757

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 6.

https://doi.org/10.1182/blood-2019-123742

Published: 2019

Journal Articles

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Laurie H Sehn, MD, Marek Trněný, MD, Kamal Bouabdallah, MD, Gregory Dueck, MD, John G. Gribben, MD DSc, P.J. Lugtenburg, MD PhD, Gilles A. Salles, MD PhD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Wenxin Liu, PhD, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2822.

https://doi.org/10.1182/blood-2019-123422

Published: 2019

Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5468.

https://doi.org/10.1182/blood-2019-124541

Published: 2019

Journal Articles

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Zhong Zheng, Li Wang, MD PhD, Shu Cheng, Pengpeng Xu, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 3984.

https://doi.org/10.1182/blood-2019-126667

Published: 2019

Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD

Blood (2019) 134 (Supplement_1): 3799.

https://doi.org/10.1182/blood-2019-123712

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD

Blood (2019) 134 (Supplement_1): 348.

https://doi.org/10.1182/blood-2019-131045

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 450.

https://doi.org/10.1182/blood-2018-99-114484

Published: 2018

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma

Nishanthan Rajakumaraswamy, MBBS, MRCP, FRCA, Eleonora Lovato, MSc, Harry Smith, BSc (Hons), Timothy Bagguley, MSc, Alexandra Smith, PhD, Russell Patmore, FRCPath, Robert Marcus, MB FRCP FRCPath

Blood (2018) 132 (Supplement 1): 5842.

https://doi.org/10.1182/blood-2018-99-114473

Published: 2018

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Blood (2018) 132 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2018-99-110555

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only